Dose-Intense Temozolomide in Recurrent Glioblastoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed
glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas.
We will be using a different dose and schedule than the FDA approved dose and schedule. The
purpose of this study is to determine if patients that have failed standard temozolomide
treatment will respond to temozolomide when given at a different dose and schedule (21 days
every 28 days).
Phase:
Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Brigham and Women's Hospital Dartmouth-Hitchcock Medical Center Massachusetts General Hospital Schering-Plough Tufts Medical Center University of Pennsylvania Wake Forest School of Medicine Wake Forest University Health Sciences